论文部分内容阅读
本研究旨在评估福建省药品联合限价阳光采购政策对药品价格、用量、医保费用和患者负担的长期影响.对2012.1-2018.8期间产生的59 968条医保报销数据进行收集汇总,处理形成月度数据后通过间断时间序列(ITS)回归模型进行分析.回归结果显示,该政策执行后,(1)竞争性药品价格显著上升,升幅达128.9％ (P＜0.01);非竞争性药品价格显著下降,降幅为18.9％ (P＜0.01).(2)样本药品用药频度显著下降,降幅达32.3％(P＜0.01);其中竞争性药品用药频度显著下降,降幅达45.9％(P＜0.01);非竞争性药品用药频度却显著上升,升幅达19.1％ (P＜0.01).(3)样本药品每人次月度总医保费用没有显著变化.(4)患者负担总体没有显著变化,但竞争性药品的自付费用显著上升,升幅达81.4％ (P＜0.01).“,”To evaluate the long-term effect of Drug Purchasing under Joint Price Caps Policy in Fujian Province on price,prescription volume,medical insurance expense and patient's burden,a total of 59 968 reimbursement records,during the period of 2012.1-2018.8,were processed into monthly data and analyzed through interrupted time series (ITS) regression models.The ITS analysis showed that after the implementation of the policy,(1) the price of competitive drugs was significantly increased by 128.9％ (P＜0.01),while the price of non-competitive drugs was significantly decreased by 18.9％ (P＜0.01).(2) The prescription volume of sample drugs was decreased by 32.3％ (P＜0.01),and that of competitive drugs was decreased by 45.9％ (P＜0.01),while that of non-competitive drugs was increased by 19.1％ (P＜0.01).(3) There was no significant change in the monthly medical insurance expense per capita of sample drugs.(4) There was no significant effect on the overall patient's burden,while the out-of-pocket payment per capita of competitive drugs was increased by 81.4％ (P＜0.01).